Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety,Tolerability,Pharmacokinetics and Pharmacodynamics Phase 1 Study of Pegfilgrastim in Chemotherapy Patients

NCT01637493 is registered in ClinicalTrials.gov with Hangzhou Jiuyuan Gene Engineering Co. Ltd., as lead sponsor.

NCT NCT01637493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01637493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety,Tolerability,Pharmacokinetics and Pharmacodynamics Phase 1 Study of Pegfilgrastim in Chemotherapy Patients
Lead sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Phase
Phase 1
Overall status
Unknown status
Start date
February 29, 2012
Completion date
June 30, 2013
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neutropenia